Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications

Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications

Novel quinolinone farnesyl transferase inhibitors are provided. These new compounds are useful in the treatment or prevention of synucleinopathies, such as Parkinson's Disease, Diffuse Lewy Body Disease, multiple system atrophy, and disorders of brain iron concentration including pantothenate k...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Lansbury, Jr, Peter T, Justman, Craig J, Fredenburg, Ross A, Meray, Robin Kate, Duggan, Mark E, Lin, Peter
Format: Patent
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Lansbury, Jr, Peter T
Justman, Craig J
Fredenburg, Ross A
Meray, Robin Kate
Duggan, Mark E
Lin, Peter
description Novel quinolinone farnesyl transferase inhibitors are provided. These new compounds are useful in the treatment or prevention of synucleinopathies, such as Parkinson's Disease, Diffuse Lewy Body Disease, multiple system atrophy, and disorders of brain iron concentration including pantothenate kinase-associated neurodegeneration (e.g., PANK1), or other neurodegenerative/neurological diseases. Provided compounds are also useful in the treatment of proliferative diseases such as cancer, and in the treatment of neurological diseases, such as cognitive impairment, depression, and anxiety. The treatment including administering to a subject a therapeutically effective amount of an inventive farnesyl transferase inhibitor compound.
format Patent
fullrecord <record><control><sourceid>uspatents_EFH</sourceid><recordid>TN_cdi_uspatents_grants_08232402</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>08232402</sourcerecordid><originalsourceid>FETCH-uspatents_grants_082324023</originalsourceid><addsrcrecordid>eNqNjbEOAjEMQ7swIOAf8gNIpx4DOwKxIrGjcJfSSCVFTTrc35OBD2CwPPjZXod86yy1uIQgYRPSpYA1FE3UUAlYMj_ZalNItYFl8pjQ3iQGNYEu0qdCvvBBy0wKKDNU55p3Z57QuIpuwyphUdr9fBPgcr6frvuu3vMtfbz81W04xjEehjj-gXwBg5tCpw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications</title><source>USPTO Issued Patents</source><creator>Lansbury, Jr, Peter T ; Justman, Craig J ; Fredenburg, Ross A ; Meray, Robin Kate ; Duggan, Mark E ; Lin, Peter</creator><creatorcontrib>Lansbury, Jr, Peter T ; Justman, Craig J ; Fredenburg, Ross A ; Meray, Robin Kate ; Duggan, Mark E ; Lin, Peter ; Link Medicine Corporation</creatorcontrib><description>Novel quinolinone farnesyl transferase inhibitors are provided. These new compounds are useful in the treatment or prevention of synucleinopathies, such as Parkinson's Disease, Diffuse Lewy Body Disease, multiple system atrophy, and disorders of brain iron concentration including pantothenate kinase-associated neurodegeneration (e.g., PANK1), or other neurodegenerative/neurological diseases. Provided compounds are also useful in the treatment of proliferative diseases such as cancer, and in the treatment of neurological diseases, such as cognitive impairment, depression, and anxiety. The treatment including administering to a subject a therapeutically effective amount of an inventive farnesyl transferase inhibitor compound.</description><language>eng</language><creationdate>2012</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8232402$$EPDF$$P50$$Guspatents$$Hfree_for_read</linktopdf><link.rule.ids>230,308,780,802,885,64038</link.rule.ids><linktorsrc>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8232402$$EView_record_in_USPTO$$FView_record_in_$$GUSPTO$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Lansbury, Jr, Peter T</creatorcontrib><creatorcontrib>Justman, Craig J</creatorcontrib><creatorcontrib>Fredenburg, Ross A</creatorcontrib><creatorcontrib>Meray, Robin Kate</creatorcontrib><creatorcontrib>Duggan, Mark E</creatorcontrib><creatorcontrib>Lin, Peter</creatorcontrib><creatorcontrib>Link Medicine Corporation</creatorcontrib><title>Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications</title><description>Novel quinolinone farnesyl transferase inhibitors are provided. These new compounds are useful in the treatment or prevention of synucleinopathies, such as Parkinson's Disease, Diffuse Lewy Body Disease, multiple system atrophy, and disorders of brain iron concentration including pantothenate kinase-associated neurodegeneration (e.g., PANK1), or other neurodegenerative/neurological diseases. Provided compounds are also useful in the treatment of proliferative diseases such as cancer, and in the treatment of neurological diseases, such as cognitive impairment, depression, and anxiety. The treatment including administering to a subject a therapeutically effective amount of an inventive farnesyl transferase inhibitor compound.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2012</creationdate><recordtype>patent</recordtype><sourceid>EFH</sourceid><recordid>eNqNjbEOAjEMQ7swIOAf8gNIpx4DOwKxIrGjcJfSSCVFTTrc35OBD2CwPPjZXod86yy1uIQgYRPSpYA1FE3UUAlYMj_ZalNItYFl8pjQ3iQGNYEu0qdCvvBBy0wKKDNU55p3Z57QuIpuwyphUdr9fBPgcr6frvuu3vMtfbz81W04xjEehjj-gXwBg5tCpw</recordid><startdate>20120731</startdate><enddate>20120731</enddate><creator>Lansbury, Jr, Peter T</creator><creator>Justman, Craig J</creator><creator>Fredenburg, Ross A</creator><creator>Meray, Robin Kate</creator><creator>Duggan, Mark E</creator><creator>Lin, Peter</creator><scope>EFH</scope></search><sort><creationdate>20120731</creationdate><title>Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications</title><author>Lansbury, Jr, Peter T ; Justman, Craig J ; Fredenburg, Ross A ; Meray, Robin Kate ; Duggan, Mark E ; Lin, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-uspatents_grants_082324023</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2012</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Lansbury, Jr, Peter T</creatorcontrib><creatorcontrib>Justman, Craig J</creatorcontrib><creatorcontrib>Fredenburg, Ross A</creatorcontrib><creatorcontrib>Meray, Robin Kate</creatorcontrib><creatorcontrib>Duggan, Mark E</creatorcontrib><creatorcontrib>Lin, Peter</creatorcontrib><creatorcontrib>Link Medicine Corporation</creatorcontrib><collection>USPTO Issued Patents</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Lansbury, Jr, Peter T</au><au>Justman, Craig J</au><au>Fredenburg, Ross A</au><au>Meray, Robin Kate</au><au>Duggan, Mark E</au><au>Lin, Peter</au><aucorp>Link Medicine Corporation</aucorp><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications</title><date>2012-07-31</date><risdate>2012</risdate><abstract>Novel quinolinone farnesyl transferase inhibitors are provided. These new compounds are useful in the treatment or prevention of synucleinopathies, such as Parkinson's Disease, Diffuse Lewy Body Disease, multiple system atrophy, and disorders of brain iron concentration including pantothenate kinase-associated neurodegeneration (e.g., PANK1), or other neurodegenerative/neurological diseases. Provided compounds are also useful in the treatment of proliferative diseases such as cancer, and in the treatment of neurological diseases, such as cognitive impairment, depression, and anxiety. The treatment including administering to a subject a therapeutically effective amount of an inventive farnesyl transferase inhibitor compound.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_uspatents_grants_08232402
source USPTO Issued Patents
title Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T00%3A50%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-uspatents_EFH&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Lansbury,%20Jr,%20Peter%20T&rft.aucorp=Link%20Medicine%20Corporation&rft.date=2012-07-31&rft_id=info:doi/&rft_dat=%3Cuspatents_EFH%3E08232402%3C/uspatents_EFH%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true